公开(公告)号：EP2258414A2

公开(公告)日：2010-12-08

申请号：EP10164082.9

申请日：2008-09-03

申请人： Japan Stent Technology Co., Ltd. ,  TOKAI UNIVERSITY EDUCATIONAL SYSTEM ,  Toyo Advanced Technologies Co., Ltd. ,  Iwata, Hiroo

发明人： Iwata, Hiroo ,  Omura, Ikuo ,  Jin, Zhen Yu ,  Yamashita, Shuzo ,  Mochizuki, Akira

IPC分类号： A61L31/10 ,  A61L31/16

CPC分类号： A61F2/82 ,  A61F2/91 ,  A61F2/915 ,  A61F2002/91541 ,  A61F2250/0067 ,  A61K9/0024 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/608 ,  A61L2420/08

摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8 : 2 to 3 : 7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 % by weight of the polymer being less than 20 % by weight.

摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架主体，至少涂覆外表面的第一涂层和基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 为8：2至3：7.另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，药物的重量组成比为聚合物的80重量％ 小于20重量％。

公开(公告)号：EP2258414A3

公开(公告)日：2014-08-27

申请号：EP10164082.9

申请日：2008-09-03

申请人： Japan Stent Technology Co., Ltd. ,  TOKAI UNIVERSITY EDUCATIONAL SYSTEM ,  Iwata, Hiroo

发明人： Iwata, Hiroo ,  Omura, Ikuo ,  Jin, Zhen Yu ,  Yamashita, Shuzo ,  Mochizuki, Akira

IPC分类号： A61L31/10 ,  A61L31/16

CPC分类号： A61F2/82 ,  A61F2/91 ,  A61F2/915 ,  A61F2002/91541 ,  A61F2250/0067 ,  A61K9/0024 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/608 ,  A61L2420/08

摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8 : 2 to 3 : 7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 % by weight of the polymer being less than 20 % by weight.